Patient data collective and research matching AI
Hyper-Care
Hyper-Care describes patient-controlled record use, sponsor choice, study matching, and shared commercial value. These remain design claims. Key custody, revocation, compensation terms, and access without research participation are not independently established.
Published September 8, 2026 as an AI-assisted draft. The public report separates documented facts, agency judgments and unresolved questions.
Summary judgment · 78 out of 100 toward patient-directed
Patient data collective and AI advocate design, including research matching and shared commercial value. Operational implementation remains unverified.
Potentially agency-expanding, with commercialization and disclosure caveats
Hyper-Care describes patient-controlled record use, sponsor choice, study matching, and shared commercial value. These remain design claims. Key custody, revocation, compensation terms, and access without research participation are not independently established.
Patient agency
How this tool changes agency
Record explanation and study discovery could support informed action. No reviewed page establishes correction or appeal of an AI inference or an eligibility exclusion.
Key custody, revocation enforcement, navigation without research participation and compensation terms remain unverified
Patient agency assessment
Who sets and changes the goal?
The described ability to select sponsors and control release is agency-relevant. Payment for contributing data does not itself establish governance rights or permission to refuse research while retaining care tools.
What can the patient understand, question, or do?
Record explanation and study discovery could support informed action. No reviewed page establishes correction or appeal of an AI inference or an eligibility exclusion.
Can the patient evaluate the conditions of use?
Transparency promises are specific but remain promises. Encryption in transit and at rest does not alone establish that only the patient can decrypt data.
Text findings
Conditions of use
Published controls and their limits
Transparency promises are specific but remain promises. Encryption in transit and at rest does not alone establish that only the patient can decrypt data.
What remains unknown?
Not tested or not established
Key custody, revocation enforcement, navigation without research participation and compensation terms remain unverified
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
Source-specific findings and retrieval limitations are recorded in the full report.
Review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Key custody, revocation enforcement, navigation without research participation and compensation terms remain unverified No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
AI-assisted draft · Low to moderate for design claims, low for operational guarantees (AI-assisted draft)